What Complamina Retard Treats: Main Uses and Benefits

The primary therapeutic role of Complamina Retard is centered on providing symptomatic support in conditions characterized by chronic, insufficient blood flow in both the peripheral limbs and the brain. Its active component is generally considered relevant for addressing both peripheral and cerebrovascular disorders. The medication is applied in addressing symptom-driven clinical presentations where poor circulation causes noticeable interference with functional stability.

---

Key Therapeutic Domains

The medication is commonly used across conditions presenting with episodic or fluctuating manifestations of circulatory impairment. These conditions often include Peripheral Vascular Disease (PVD), cerebrovascular insufficiency, and circumstances involving chronic ischemic tissue damage. It helps address symptom clusters that interfere with daily functioning, including leg pain and cramping (intermittent claudication), persistent numbness or coldness in the extremities, and episodes of vertigo or dizziness related to reduced cerebral blood flow.

Patient Benefits

Complamina Retard provides supportive relief that contributes to easing the overall symptom load. This is relevant when supportive symptom management is appropriate, such as during phases of increased distress or discomfort related to poor circulation. This assists with maintaining functional stability and supports the patient during difficult episodes by contributing to easing the overall symptom load and helping improve day-to-day comfort.

---

Quick Fact: Relief for Ischemic Limb Pain

(Used to manage the symptomatic discomfort and cramping in the legs that is caused by restricted blood flow.)

Eligibility Map: Who Can and Cannot Use Complamina Retard — Official Regulatory Information

Eligibility Scope

The use of Complamina Retard is generally intended for adults and adolescents (over 18 years) who do not possess any labeled exclusions.

Populations for whom use is contraindicated:

Use is absolutely prohibited in patients with known hypersensitivity to Xantinol Nicotinate or other xanthine derivatives. The medicine is also contraindicated in patients who have recently suffered a Myocardial Infarction, have Congestive Heart Failure, or have a condition involving Acute Hemorrhage or severe bleeding disorders.

Age-related eligibility rules:

The medicine is generally not recommended for use in the pediatric population as its safety and efficacy have not been formally established in children.

Condition-specific eligibility rules:

The use of Complamina Retard requires caution and close monitoring in patients with Severe Renal Impairment, Severe Hepatic Impairment, Severe Hypotension (low blood pressure), and Mitral Stenosis.

Pregnancy and lactation eligibility status:

Use is generally not recommended or contraindicated during pregnancy and is not recommended while breastfeeding.

Connection to the overall eligibility profile:

Official regulatory documents define who can and cannot use the medicine by listing absolute contraindications that prohibit use due to critical safety risks. Eligibility for the standard adult patient population is conditional upon the absence of severe cardiovascular events and the status of specific organ functions, which require defined caution if impaired.

Interactions with other medicines and products

The interaction profile for Complamina Retard (Xantinol Nicotinate) is defined by its core action as a peripheral vasodilator, leading primarily to pharmacodynamic interactions as documented in official regulatory summaries. No specific pharmacokinetic interaction profile involving Cytochrome P450 (CYP) enzymes or drug transporters is formally documented in government-cited information.

---

Documented Pharmacodynamic Interactions

Product Category
Antihypertensive Agents (e.g., ACE inhibitors, Calcium Channel Blockers)
Other Vasodilators (e.g., Nitrates, Prostaglandin Analogs)
Anticoagulants and Antiplatelet Drugs

Co-administration with Antihypertensive Agents or Other Vasodilators may result in additive hypotensive effects, leading to a reinforced clinical effect on blood pressure. The co-administration of Anticoagulants or Antiplatelet Drugs may enhance the pharmacodynamic effect of these agents, increasing the documented risk of bleeding or hemorrhage.

---

Substance Interactions and Regulatory Constraints

Substance / Constraint	Official Regulatory Statement
Alcohol (Ethanol)	Increases the risk of low blood pressure due to an additive effect.
Contraindicated Combinations	No formal drug-drug combination is listed as an absolute contraindication.
Timing Requirements	No mandatory time-separation rules for administration are documented.

These patterns structure the official profile, identifying agents that require monitoring due to the potential for enhanced clinical effects related to vasodilation or anticoagulation.

How Complamina Retard Works

Complamina Retard (Xantinol Nicotinate) acts through a complementary two-part mechanism that targets both vascular tone and the physical properties of blood components, leading to increased peripheral blood flow.

---

Dual Action on Vascular Tone and Smooth Muscle

The drug provides two separate molecular pathways for reducing the resistance to blood flow. The first involves the Nicotinic Acid component, which promotes the local release of Prostaglandins. These mediators activate receptors on vascular smooth muscle cells, resulting in relaxation. Simultaneously, the Xanthinol component inhibits Phosphodiesterase (PDE) enzymes, causing a rise in intracellular cAMP/cGMP. This dual-pathway modulation reduces tension in the vessel walls, leading to the widening of the blood vessels and a reduction in peripheral vascular resistance.

---

Modulating Microcirculation and Cellular Energy

In addition to widening the vessels, the mechanism influences blood flow at the capillary level. The Xanthinol component increases ATP levels within the red blood cells, which increases their flexibility and deformability. This physical change allows the blood cells to navigate narrow peripheral capillaries more efficiently. This rheological adjustment supports the translation of increased blood flow volume into enhanced oxygen and nutrient delivery to the downstream tissues.

Instruction Map: How to use Complamina Retard

Property	Description
Route of administration:	Oral route is the method for the 500 mg Sustained-Release tablet. The active compound, Xantinol Nicotinate, is also administered via the Intravenous (IV) route in other formulations and clinical settings.
Dosing schedule:	The standard unit dose is 500 mg. Maintenance regimens typically involve a total daily dose between 1000 mg and 1500 mg, achieved by divided administration.
Timing in relation to meals (if applicable):	The dose is taken with or immediately after meals (with liquid) to support tolerability.
Preparation requirements (if applicable):	The tablet requires no dilution or reconstitution.
Age-group administration rules:	Dosing is standardized for adults. Instructions indicate dose adjustment or close monitoring for patients with renal impairment or hepatic impairment.
Missed-dose rules:	Specific missed-dose instructions are not consistently documented for this product.
Special procedural conditions:	The Sustained-Release tablet must be swallowed whole. It is prohibited to chew, crush, or break the tablet, as this action compromises the controlled-release mechanism.

---

Instruction Classifications (High-Level)

Property	Description
Administration method type:	Oral.
Frequency pattern:	Divided Daily (typically two to three times per day).
Use-context constraints:	Food-Dependent Intake.

---

Resulting Procedural Structure

Procedural step sequence:

• Take the 500 mg tablet by the oral route.
• Ensure the tablet is taken with or immediately after a meal.
• Swallow the entire tablet whole with water, without crushing or chewing.
• Repeat the unit dose according to the divided daily schedule (typically twice daily) for the specified course duration.

Connection to the overall use protocol: The protocol for Complamina Retard is structured to ensure the active ingredient, Xantinol Nicotinate, is released slowly and consistently over time. The mandatory handling rule (swallowing the tablet whole) and the frequency pattern are designed to maintain therapeutic consistency. This standardized procedure outlines the method for using the medicine.

Research Evidence / Overview of Studies for Complamina Retard

Evidence for Use in Chronic Lower Limb Circulation Issues

The research for Complamina Retard has focused on conditions characterized by functional limitations, such as intermittent claudication, where patients experience outcomes related to physical discomfort like cramping or pain in the legs. The evidence available primarily consists of historical double-blind controlled trials and long-term observational studies. Research explored how symptoms evolved in the observed populations, and studies monitored measures like walking distance and patient-reported outcomes describing perceived discomfort and outcomes related to rest pain.

These studies also examined physiological outcomes, including the Ankle Brachial Pressure Index (ABPI), and parameters related to blood flow, such as whole-blood viscosity. Research highlights changes measured during the study period for these markers, but findings were mixed and heterogeneous across the existing historical literature. The overall evidence base for this indication is labeled as having low to moderate certainty.

Studies on Cerebrovascular Function and Cognitive Support

Complamina Retard was also studied for its application in conditions associated with acute or disruptive episodes, such as cerebrovascular insufficiency, which may present with symptoms like vertigo or dizziness. The studies explored in this area were primarily psychometric double-blind controlled trials. These trials were applied in research contexts involving fluctuating or unstable symptoms and functional imbalance.

Researchers examined various functional outcomes related to daily functioning, including short-term memory performance and sensory register function, using psychometric testing scales. Studies also explored outcomes linked to metabolism, such as outcomes related to cellular energy status. The research describes patterns observed in these studies, but these findings often rely on functional or surrogate endpoints rather than on hard clinical outcomes (e.g., stroke prevention).

What is Still Uncertain About the Research

The evidence for Complamina Retard is characterized by several key limitations that contribute to low certainty. Evidence quality varies across studies, and the majority of the primary trials are historical and dated, meaning they predate modern international standards for randomized controlled trials. These trials often involved modest sample sizes.

Because comparative evidence is lacking and data are still emerging in some areas, the results apply only to the specific conditions under which they were conducted. This research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The current evidence base is noted to lack the consistent, large-scale, high-quality trials that would provide a clear understanding of patterns.

Common questions about Complamina Retard (FAQ)

Q: What is Complamina Retard used for?

A: Complamina Retard contains the active ingredient Xantinol Nicotinate. It is primarily used to manage conditions related to poor blood circulation in the limbs and the brain. This includes disorders such as peripheral vascular disease (PVD) and cerebrovascular disorders, which are caused by narrowed blood vessels.

---

Q: How does Complamina Retard work in the body?

A: The active component, Xantinol Nicotinate, is a peripheral vasodilator. It works by widening the blood vessels, particularly the smaller ones (arterioles and capillaries). This dilation helps to increase blood flow to the affected areas, such as the limbs and the brain, thereby improving circulation.

---

Q: What are the common side effects of Complamina Retard?

A: The most common side effect is flushing, which is a sense of warmth, redness, or tingling, especially in the face and neck. Other common side effects may include:

• Headache
• Dizziness
• Gastrointestinal disturbances (e.g., nausea, vomiting, stomach upset)

These side effects are generally mild and often improve as the body adjusts to the medication. If side effects persist or are severe, consult a doctor.

---

Q: Should Complamina Retard be taken with food?

A: It is generally recommended to take Complamina Retard with food (or milk or an antacid). Taking it with food can help to reduce the risk of stomach upset and may also help lessen the flushing side effect.

---

Q: What if I miss a dose of Complamina Retard?

A: If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

---

Q: Who should not take Complamina Retard?

A: Complamina Retard should generally be avoided by individuals who:

• Have a known allergy to Xantinol Nicotinate or any component of the tablet.
• Have certain severe heart conditions, such as severe hypotension (very low blood pressure) or acute myocardial infarction (recent heart attack).
• Have active arterial bleeding.

Always discuss your full medical history with your doctor to ensure the medication is safe for you.

The official regulatory requirements for Complamina Retard (Xantinol Nicotinate) detail specific conditions necessary to preserve the stability and integrity of the sustained-release tablets.

---

Storage Requirements

The medication must be stored in a cool and dry place, requiring the temperature to remain below 30 C to avoid degradation. It is mandatory to protect the tablets from direct sunlight and excessive moisture.

---

Child Safety and Disposal

A critical storage requirement is to keep the medicine out of the sight and reach of children.

Regarding disposal, the product must be used before the expiration date stated on the packaging. Unused or expired medication should be disposed of in accordance with local regulatory guidelines for pharmaceutical waste.